August 22, 2025
Oculis Reports Q2 2025 Financial Results and Provides Company Update
ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) — Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and…
Pharmaceuticals, Biotechnology and Life Sciences
ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) — Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and…
Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmologyOCS-01: Both pivotal Ph3 DIAMOND trials are fully…
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces…
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to…
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth QuarterCAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) — Larkspur…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
Investment to support NovaBay’s continued public listing and provide funding for a future strategic transactionEMERYVILLE, Calif., Aug. 19, 2025 (GLOBE…
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is…
Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did…
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd…